FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class
Tag: scPharmaceuticals
scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes
BURLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today […]
scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Announced launch and commercial availability of FUROSCIX® on February 20th Generated net FUROSCIX revenue of $2.1 million Ended Q1 2023 with cash, cash equivalents and short-term investments of $116.1 million Company to host investor conference call and webcast today, Wednesday, May […]
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today […]
scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update
Commercial launch planned for February 20, 2023 BURLINGTON, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce […]
scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer
Appointment brings more than 20 years of life sciences finance leadership experience to the CFO role BURLINGTON, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the […]
scPharmaceuticals Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
Announced FDA marketing approval of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure Entered into a secured debt financing agreement for up to $100 million with funds managed […]
UPDATE – scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure
FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide Commercial launch planned in Q1 2023 BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing […]
scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree
Funds to be used to facilitate U.S. commercial launch of FUROSCIX® BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery […]
scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
Announced FDA acceptance of FUROSCIX® New Drug Application and Prescription Drug User-Fee Act target action date of October 8, 2022 Continued to advance commercial readiness activities in support of an anticipated Q4 2022 launch of FUROSCIX, if approved Ended Q2 with […]
Recent
New Data Demonstrates Vektor Medical’s AI-Powered vMap Algorithm Achieves 91% Accuracy in Distinguishing Epicardial and Endocardial Ventricular Tachycardia, Markedly Surpassing Visual ECG Analysis
Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025
Genomadix Inc. Enters into Collaboration with Mayo Clinic on Precision Medicine for Telestroke
Popular
- No commented posts yet